NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

The shot is also cleared for individuals between 12 and 64 years of age who are at least one risk factor as defined by the ...

Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...

The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.

The U.S. Department of Health and Human Services has removed mRNA COVID-19 vaccines from children and pregnant women’s ...

A new material developed at Cornell University could significantly improve the delivery and effectiveness of mRNA vaccines by ...

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults.

A new material developed at Cornell University could significantly improve the delivery and effectiveness of mRNA vaccines by ...

Moderna has withdrawn the BLA for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after consulting with FDA.